Cite

HARVARD Citation

    Ho, C. et al. (2021). HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. European journal of cancer. pp. 16-23. [Online]. 
  
Back to record